20 Jan Welcome to Capella BioScience
Innovation through technology
Our strategy is to use innovative technologies to develop novel medicines based on monoclonal antibodies (mAbs) to the next generation of important therapeutic targets in oncology and autoimmune disease.
Our leadership team have proven track records of successfully developing marketed therapeutic biologics and growing multibillion dollar companies.
Founded in 2014, by Advent Life Sciences and Index Ventures, our mission is to advance our pipeline of first-in-class mAb therapeutics in areas of high unmet medical need
Early Stage Pipeline
We are developing a strong portfolio of mAbs in oncology and autoimmune disease. Our most advanced assets will enter preclinical development in 2015
Capella BioScience discovers and develops mAbs both independently and in collaboration with biotechnology and academic partners.
We are employing our proprietary technologies to discover, develop and commercialise monoclonal antibody medicines to difficult and novel drug targets.